Wedbush Equities Analysts Boost Earnings Estimates for Inozyme Pharma, Inc. (NASDAQ:INZY)

Inozyme Pharma, Inc. (NASDAQ:INZYFree Report) – Analysts at Wedbush raised their Q2 2024 earnings estimates for Inozyme Pharma in a research report issued on Tuesday, May 7th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.40) for the quarter, up from their previous estimate of ($0.41). Wedbush currently has a “Outperform” rating and a $15.00 target price on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.46) per share. Wedbush also issued estimates for Inozyme Pharma’s FY2024 earnings at ($1.66) EPS, Q2 2025 earnings at ($0.38) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.47) EPS and FY2027 earnings at ($0.04) EPS.

INZY has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Inozyme Pharma in a research report on Wednesday, March 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a research note on Wednesday. Finally, Bank of America reduced their price target on Inozyme Pharma from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, April 9th.

View Our Latest Research Report on Inozyme Pharma

Inozyme Pharma Trading Up 0.2 %

NASDAQ INZY opened at $4.65 on Friday. The firm’s 50-day moving average is $5.59 and its two-hundred day moving average is $4.75. Inozyme Pharma has a 12 month low of $2.69 and a 12 month high of $7.80. The company has a debt-to-equity ratio of 0.32, a current ratio of 13.36 and a quick ratio of 13.36. The stock has a market capitalization of $287.65 million, a P/E ratio of -3.35 and a beta of 1.54.

Inozyme Pharma (NASDAQ:INZYGet Free Report) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.04).

Insider Buying and Selling

In other news, CEO Douglas A. Treco sold 7,523 shares of the stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now owns 20,665 shares of the company’s stock, valued at $143,415.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 11.88% of the stock is owned by insiders.

Institutional Trading of Inozyme Pharma

Several institutional investors have recently added to or reduced their stakes in INZY. SG Americas Securities LLC increased its position in shares of Inozyme Pharma by 46.9% in the 4th quarter. SG Americas Securities LLC now owns 21,236 shares of the company’s stock worth $90,000 after purchasing an additional 6,784 shares during the last quarter. Strs Ohio bought a new position in Inozyme Pharma during the 3rd quarter worth approximately $41,000. Values First Advisors Inc. acquired a new position in shares of Inozyme Pharma in the 4th quarter worth approximately $59,000. Eventide Asset Management LLC increased its holdings in shares of Inozyme Pharma by 1.8% in the 4th quarter. Eventide Asset Management LLC now owns 3,179,837 shares of the company’s stock valued at $13,546,000 after acquiring an additional 54,837 shares during the last quarter. Finally, CHI Advisors LLC raised its position in shares of Inozyme Pharma by 6.3% during the 3rd quarter. CHI Advisors LLC now owns 1,270,027 shares of the company’s stock valued at $5,334,000 after acquiring an additional 75,000 shares in the last quarter. 88.30% of the stock is owned by institutional investors and hedge funds.

Inozyme Pharma Company Profile

(Get Free Report)

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.

See Also

Earnings History and Estimates for Inozyme Pharma (NASDAQ:INZY)

Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with's FREE daily email newsletter.